{"title":"日本临床实践中口服西马鲁肽治疗成人2型糖尿病的多中心、前瞻性、真实世界研究（PIONEER REAL Japan）：亚组分析。","authors":"Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, Rimei Nishimura, Yasuo Terauchi, Hanan Amadid, Uffe Christian Braae, Atheline Major-Pedersen, Ryo Suzuki","doi":"10.1111/jdi.70099","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>HbA<sub>1c</sub> and body weight were assessed across selected subgroups of adults with type 2 diabetes receiving oral semaglutide in clinical practice.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>In this non-interventional study, changes in HbA<sub>1c</sub> and body weight to end of study (EoS) and safety were assessed by subgroup: baseline age, body mass index (BMI), type 2 diabetes duration, participants switching from dipeptidyl peptidase-4 inhibitors, and semaglutide dose at EoS.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>All subgroups experienced reductions in HbA<sub>1c</sub> and body weight. Younger participants had greater reductions in HbA<sub>1c</sub> than older participants (−0.9, −0.7, −0.7, and −0.5 percentage points for participants aged <55, ≥55–<65, ≥65–<75, and ≥75 years, respectively [<i>P</i> = 0.0467]). Shorter type 2 diabetes duration and lower EoS semaglutide dose were associated with greater HbA<sub>1c</sub> reductions (−0.8, −0.7, and −0.6 percentage points with ≤5, >5–≤10, and >10 years' duration, respectively [<i>P</i> < 0.0001]; −1.2, −0.7, and −0.4 percentage points with 3, 7, and 14 mg, respectively [<i>P</i> < 0.0001]). Changes in HbA<sub>1c</sub> were not significantly different across other subgroups. Lower EoS semaglutide dose was associated with greater body weight reductions (−3.8, −2.9, and −2.8 kg with 3, 7, and 14 mg, respectively [<i>P</i> < 0.0001]); body weight reductions were not significantly different across other subgroups. Adverse events were similar between subgroups, except that older subgroups experienced more events.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>HbA<sub>1c</sub> and body weight decreased across all subgroups, providing insights into oral semaglutide use in clinical practice for individuals with different characteristics in the real-world setting.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"16 10","pages":"1794-1807"},"PeriodicalIF":3.0000,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70099","citationCount":"0","resultStr":"{\"title\":\"A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses\",\"authors\":\"Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, Rimei Nishimura, Yasuo Terauchi, Hanan Amadid, Uffe Christian Braae, Atheline Major-Pedersen, Ryo Suzuki\",\"doi\":\"10.1111/jdi.70099\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Aims</h3>\\n \\n <p>HbA<sub>1c</sub> and body weight were assessed across selected subgroups of adults with type 2 diabetes receiving oral semaglutide in clinical practice.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>In this non-interventional study, changes in HbA<sub>1c</sub> and body weight to end of study (EoS) and safety were assessed by subgroup: baseline age, body mass index (BMI), type 2 diabetes duration, participants switching from dipeptidyl peptidase-4 inhibitors, and semaglutide dose at EoS.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>All subgroups experienced reductions in HbA<sub>1c</sub> and body weight. Younger participants had greater reductions in HbA<sub>1c</sub> than older participants (−0.9, −0.7, −0.7, and −0.5 percentage points for participants aged <55, ≥55–<65, ≥65–<75, and ≥75 years, respectively [<i>P</i> = 0.0467]). Shorter type 2 diabetes duration and lower EoS semaglutide dose were associated with greater HbA<sub>1c</sub> reductions (−0.8, −0.7, and −0.6 percentage points with ≤5, >5–≤10, and >10 years' duration, respectively [<i>P</i> < 0.0001]; −1.2, −0.7, and −0.4 percentage points with 3, 7, and 14 mg, respectively [<i>P</i> < 0.0001]). Changes in HbA<sub>1c</sub> were not significantly different across other subgroups. Lower EoS semaglutide dose was associated with greater body weight reductions (−3.8, −2.9, and −2.8 kg with 3, 7, and 14 mg, respectively [<i>P</i> < 0.0001]); body weight reductions were not significantly different across other subgroups. Adverse events were similar between subgroups, except that older subgroups experienced more events.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>HbA<sub>1c</sub> and body weight decreased across all subgroups, providing insights into oral semaglutide use in clinical practice for individuals with different characteristics in the real-world setting.</p>\\n </section>\\n </div>\",\"PeriodicalId\":51250,\"journal\":{\"name\":\"Journal of Diabetes Investigation\",\"volume\":\"16 10\",\"pages\":\"1794-1807\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jdi.70099\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Diabetes Investigation\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70099\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70099","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
A multicenter, prospective, real-world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice (PIONEER REAL Japan): Subgroup analyses
Aims
HbA1c and body weight were assessed across selected subgroups of adults with type 2 diabetes receiving oral semaglutide in clinical practice.
Methods
In this non-interventional study, changes in HbA1c and body weight to end of study (EoS) and safety were assessed by subgroup: baseline age, body mass index (BMI), type 2 diabetes duration, participants switching from dipeptidyl peptidase-4 inhibitors, and semaglutide dose at EoS.
Results
All subgroups experienced reductions in HbA1c and body weight. Younger participants had greater reductions in HbA1c than older participants (−0.9, −0.7, −0.7, and −0.5 percentage points for participants aged <55, ≥55–<65, ≥65–<75, and ≥75 years, respectively [P = 0.0467]). Shorter type 2 diabetes duration and lower EoS semaglutide dose were associated with greater HbA1c reductions (−0.8, −0.7, and −0.6 percentage points with ≤5, >5–≤10, and >10 years' duration, respectively [P < 0.0001]; −1.2, −0.7, and −0.4 percentage points with 3, 7, and 14 mg, respectively [P < 0.0001]). Changes in HbA1c were not significantly different across other subgroups. Lower EoS semaglutide dose was associated with greater body weight reductions (−3.8, −2.9, and −2.8 kg with 3, 7, and 14 mg, respectively [P < 0.0001]); body weight reductions were not significantly different across other subgroups. Adverse events were similar between subgroups, except that older subgroups experienced more events.
Conclusions
HbA1c and body weight decreased across all subgroups, providing insights into oral semaglutide use in clinical practice for individuals with different characteristics in the real-world setting.
期刊介绍：
Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
